Literature DB >> 448195

Long-term epidemiology of infections with Mycoplasma pneumoniae.

H M Foy, G E Kenny, M K Cooney, I D Allan.   

Abstract

Pneumonia due to Mycoplasma pneumoniae was monitored in a large prepaid medical-care group in Seattle, Washington, between 1963 and 1975. The disease was diagnosed by isolation of M. pneumoniae and/or significant rises in titer of complement-fixing (antilipid) antibody in paired sera. Infection was endemic without significant seasonal fluctuations. Two epidemics occurred: the first peaked in January 1967, the second late in the summer of 1974. Total rates of pneumonia infection in children increased during M. pneumoniae epidemics, but epidemics of infection with respiratory syncytial virus had a greater effect. Age-specific attack rates for M. pneumoniae pneumonia among children aged five to nine years (about six per 1,000) were about twice the rates for younger children and four times those for adults. Serologic study of healthy schoolchildren showed annual rates of infection that paralleled but greatly exceeded rates of recognized M. pneumoniae pneumonia. Infection rates varied from 2% in endemic years to 35% in epidemic periods. A higher proportion of infections among children aged five to nine years than among adolescents aged 15-19 years resulted in pneumonia.

Entities:  

Mesh:

Year:  1979        PMID: 448195     DOI: 10.1093/infdis/139.6.681

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  88 in total

1.  Genotyping of Mycoplasma pneumoniae clinical isolates reveals eight P1 subtypes within two genomic groups.

Authors:  J W Dorigo-Zetsma; J Dankert; S A Zaat
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

2.  Rapid, sensitive detection of Mycoplasma pneumoniae in simulated clinical specimens by DNA amplification.

Authors:  G E Buck; L C O'Hara; J T Summersgill
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

3.  Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Identification of a possible cytadherence regulatory locus in Mycoplasma pneumoniae.

Authors:  C T Hedreyda; D C Krause
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 5.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

Authors:  K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; N Suyama; K Tomono
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.

Authors:  M Kaku; K Ishida; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; K Tomono; N Suyama
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Mycoplasma contamination of murine embryonic stem cells affects cell parameters, germline transmission and chimeric progeny.

Authors:  Kyriaki Markoullis; Diana Bulian; Gabriele Hölzlwimmer; Leticia Quintanilla-Martinez; Katrin-Janine Heiliger; Horst Zitzelsberger; Hagen Scherb; Josef Mysliwietz; Cord C Uphoff; Hans G Drexler; Thure Adler; Dirk H Busch; Jörg Schmidt; Esther Mahabir
Journal:  Transgenic Res       Date:  2008-09-26       Impact factor: 2.788

9.  Are outbreaks and sporadic respiratory infections by Mycoplasma pneumoniae due to two distinct subtypes?

Authors:  E Jacobs; M Vonski; K Oberle; O Opitz; K Pietsch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

10.  A novel IL-17-dependent mechanism of cross protection: respiratory infection with mycoplasma protects against a secondary listeria infection.

Authors:  Amy N Sieve; Karen D Meeks; Sheetal Bodhankar; Suheung Lee; Jay K Kolls; Jerry W Simecka; Rance E Berg
Journal:  Eur J Immunol       Date:  2009-02       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.